that additional factors are required. Our study also confirmed the association of FLG mutations and early-onset infantile eczema, which is in line with previous work. 6 Our ability to interrogate the role of sensitization in the relationship between FLG mutations and food allergy in a large population-based, age-matched, challenge-proved food allergy cohort is a major and novel strength of this work. There is some potential participation bias among negative control subjects (higher immediate family history of allergic diseases compared with the general population); however, such a bias would be more likely to create a false-negative than a false-positive association.
Egg-allergic patients can be safely vaccinated against influenza
To the Editor:
As the influenza vaccine contains residual egg protein, its administration to egg-allergic patients had always raised theoretical concerns about anaphylaxis. 1 We report our experience with the vaccination of egg-allergic patients with a trivalent inactivated seasonal influenza vaccine administered during 5 seasons (2007) (2008) (2009) (2010) (2011) and summarize the current published clinical experience with these patients.
We conducted a prospective cohort study recruiting and vaccinating egg-allergic patients in 2010-2011 and 2011-2012 in 5 Canadian hospitals (Montreal, Quebec City, Sherbrooke, Edmonton, and Vancouver). Egg allergy was defined as a history of at least 1 sign or symptom of allergy (cutaneous, ocular, respiratory, gastrointestinal, or cardiovascular symptoms) occurring within 60 minutes of egg ingestion, and the confirmation of persistent sensitization to egg (within 6 months of vaccination) shown by a skin prick test response to egg at least 3 mm larger than that of the saline control within 10 to 15 minutes, or an egg-specific IgE level of 0.35 kU/L or more (UniCAP, Pharmacia). In 2010-2011, we recruited all patients with allergy to egg, whereas in 2011-2012, the recruitment focused on patients with severe allergic reaction defined as the occurrence of anaphylaxis or cardiorespiratory symptoms upon egg ingestion. In both years, patients (or their parents/legal guardian if minor patients) had to provide written consent for the collection of data on adverse events occurring within 24 hours following vaccination. We also performed a retrospective cohort study of all egg-allergic patients referred for administration of seasonal influenza at the Sainte-Justine Hospital in Montreal, during the [2007] [2008] [2008] [2009] , and 2009-2010 vaccination seasons. The definition of egg allergy and the threshold for skin prick test were the same as previously described, but the method of detection of specific IgE was the Immulite immunoassay system (Siemens, Muenchen, Germany). For both cohorts, patients were examined immediately before vaccination, remained under observation for 60 minutes postvaccination, and were then reexamined for any sign of allergic reaction. The vaccine used during all 5 seasons was the split-virion trivalent inactivated influenza vaccine Fluviral manufactured by GSK (Quebec City, Quebec, Canada). The ovalbumin content for the lots used was provided by the manufacturer: 0.09 mg/mL in 2007-2008, 0.03 mg/mL in 2008-2009, 0.31 mg/mL in 2009-2010, up to 0.2 mg/mL in 2010-2011, and up to 0.06 mg/mL for 2011-2012. The primary outcome was the occurrence of anaphylaxis according to the Brighton Collaboration definition. 2 The study was approved by the ethics boards of all participating hospitals.
Over 5 influenza seasons, 457 doses of trivalent inactivated seasonal influenza vaccines were administered to 367 patients among whom 132 (153 doses) had a history of severe allergy to egg (see Table E1 in this article's Online Repository at www. jacionline.org). Four patients reported mild allergic-like symptoms after previous influenza vaccination (1 urticaria, 2 vomiting, and 1 eczema), but none experienced an adverse event when given the current vaccine. While 13 patients developed mild allergic-like symptoms in the 24 hours following vaccination, none of the 367 patients developed anaphylaxis.
We then did a literature review and retrieved articles in English or French in which at least 25 egg-allergic patients had been vaccinated. PubMed was searched with the following MESH: (influenza AND (vaccination or vaccine)) AND (egg AND (allergy OR allergic)). Further studies or conference abstracts were identified by citations in retrieved articles and by consultation with experts. Among the 87 articles retrieved from PubMed, 16 were studies including the vaccination of 25 or more eggallergic patients. We additionally found 10 conference abstracts of studies with the same minimal number of patients. Together, these 26 studies and the current study have enrolled 4172 patients including 513 who were identified as patients with a history of severe reactions (Table I) . These patients received a total of 4729 doses, and none developed anaphylaxis. With no anaphylaxis after 4729 doses of vaccine, the 95% Clopper-Pearson exact CI of the risk of anaphylaxis ranges from 0% to 0.08% (or 0 to 1 of 1250 doses). 3 For the 597 doses administered to the 513 patients with a history of severe allergic reaction to egg, the exact 95% CI of the risk of anaphylaxis ranges from 0% to 0.62% (or 0 to 1 of 161 doses). Their risk of anaphylaxis is in fact smaller as many studies in Table I had patients with severe allergy but simply did not report the information regarding their number.
The clinical experience with influenza vaccination in eggallergic patients in our cohorts and in other studies displayed in Table I has limitations. The amount of ovalbumin varied in the different influenza vaccines used and was sometimes unknown or low. Patients rarely had a recent positive food challenge confirming the persistence of egg allergy. Some studies included young children with atopic conditions (eg, atopic dermatitis) who had never eaten eggs but had a positive skin test result and high levels of egg-specific IgE. These sensitized patients are typically managed with recommendations of food avoidance as if they were allergic, although the diagnosis of allergy for these patients may be inaccurate. Despite these limitations, the patients in Table I are representative of patients managed as egg-allergic and the large number vaccinated with no ensuing anaphylaxis constitutes a strong scientific basis for new recommendations.
Egg allergy is the second most frequent food allergy and affects 1% to 2% of young children. 4 While most patients will eventually develop tolerance to eggs, it will still be present in more than 60% by 6 years of age. 5 In the United States, this grossly corresponds to 150,000 to 250,000 influenza vaccine-eligible preschoolers. Many of these patients have not benefited from the influenza vaccine in the past because of the fear of anaphylaxis or the difficulty of accessing an allergist as is often recommended. 1 Paradoxically, given their young age and the high rate of concurrent asthma, these patients have a higher risk of complications from influenza and are among those most likely to benefit from this vaccine. 6 The evidence gathered over the past 15 years is overwhelmingly reassuring that this risk is minimal. The published number of egg-allergic patients safely vaccinated against influenza is nearly 4 times as large as the number that ended the precautions regarding measles, mumps and rubella (MMR) vaccine (4172 vs 1227). 7 There will always be a very small risk of anaphylaxis associated with influenza or any other vaccination, but there is now robust evidence that egg-allergic patients, even those with severe allergy, can be safely vaccinated against influenza. The risk of anaphylaxis appears sufficiently low for patients with egg allergy to be vaccinated like all other individuals, without requiring administration by an allergist. or is on the speakers' bureau for Abbott, Merck, and Nestl e. The rest of the authors declare that they have no relevant conflicts of interest.
Obesity is not a risk factor for repeat epinephrine use in the treatment of anaphylaxis
Epinephrine is widely accepted as the first-line treatment for all forms of anaphylaxis. 1, 2 Approximately 10% to 20% of the patients treated with epinephrine for anaphylaxis receive a second dose, [3] [4] [5] [6] but the risk factors associated with repeat epinephrine use remain poorly defined. Previous studies have suggested that epinephrine administration with autoinjectors may be influenced by a patient's body habitus. 7 Therefore, we sought to determine whether obesity increases the risk for requiring 21 epinephrine doses among patients who present to the emergency department (ED) with anaphylaxis due to food allergy or stinging insect hypersensitivity.
We 1, 2001 1, , to December 31, 2006 . We identified all patients presenting to the ED for food allergy or stinging insect hypersensitivity by using relevant International Classification of Diseases, Clinical Modification Codes, Ninth Revision, 8 including 558.3 (allergic gastroenteritis), 693.1 (dermatitis due to food), 708.0 to 708.9 (urticaria), 989.5 (toxic effect due to venom), 995.0 (other anaphylactic shock), 995.1 (angioneurotic edema), 995.3 (allergy, unspecified), 995.60 (anaphylactic shock due to unspecified food), 995.61 to 995.69 (anaphylactic shock due to a specified food), and 995.7 (other adverse food reactions, not elsewhere classified). Cases were confirmed by allergist review. We focused on the total number of epinephrine treatments given during an anaphylaxis episode (including before and during the ED visit) and the patient's anthropomorphic data. Weight and height measurements documented at the ED visit were preferentially used. If measurements had been taken more than 3 months from the ED visit, height/weight at the time of the ED visit was estimated by using Centers for Disease Control and Prevention growth charts in children (<18 years) and estimates of average weight gain in US adults. Calculated body mass indexes were classified according to Centers for Disease Control and Prevention growth indicators as underweight, healthy, overweight, or obese. Medians with interquartile ranges were presented for continuous variables that were not normally distributed. Comparisons between groups were evaluated by using Kruskal-Wallis rank sum tests for continuous variables and the x 2 test or the Fisher exact test for categorical variables, as appropriate. Multivariable models were performed using logistic regression. A 2sided P value of less than .05 was considered statistically significant.
The study population comprised 321 ED patients (261 children and 60 adults) who received epinephrine for anaphylaxis and had data for both height and weight; 267 (83%) received 1 dose of epinephrine, while 54 (17%) received 21 doses. There was no difference in the need for additional doses of epinephrine between children and adults (P 5 .94) and no difference among the 4 institutions (P 5 .60). Demographic data, reaction history, and ED treatments are summarized in Table I . Patients had a median age of 8.5 (intraquartile range 3.0-16.4) years, and 47% were males. When comparing patients who received 1 and 21 doses of epinephrine, there was no difference in the inciting allergen, organ system involvement, or timing/dosing of epinephrine. While those receiving 21 doses of epinephrine were more likely to receive b-agonists, there was no significant difference in other adjunctive medications, including corticosteroids (85% vs 79%; P 5 .38).
Overall, 27 (8%) patients were underweight, 168 (52%) healthy weight, 57 (18%) overweight, and 69 (22%) obese. The distribution of body mass index categories was similar in those receiving 1 versus 21 doses (P 5 .83). There was no difference when separately examining these distributions among children (P 5 .92) and adults (P 5 .81). There was also no significant association when comparing categories of underweight/healthy versus overweight/obese (data not shown). Finally, when adjusting for age and sex, there remained no significant association between obesity (vs nonobesity) and receiving 21 doses (odds ratio 1.22; 95% CI 0.77-1.93; P 5 .40).
Anaphylaxis is a potentially life-threatening medical emergency that is frequently incited by exposure to foods or stinging insects. 1 The primary treatment for anaphylaxis is the prompt administration of epinephrine. Current practice guidelines recommend that all patients at risk for anaphylaxis receive a prescription for an epinephrine autoinjector and education on its proper use. 1, 2 Furthermore, on the basis of recently published data that 10% to 20% of the patients require repeat dosing, [3] [4] [5] [6] experts now recommend that patients at risk for anaphylaxis always carry 2 doses. 2 Our current analysis-based on a partially overlapping population of ED patients who were included in our previous studies 5,6 -is consistent with the reported percentages of anaphylaxis patients who require repeat doses of epinephrine.
Repeat dosing could be a result of biphasic reactions or inadequate treatment response. In prior work, 5 we reported that most patients received the second dose within 1 hour of the first dose, suggesting that inadequate treatment response was the more likely explanation. Lack of response to epinephrine could be a result of failure to administer it in a timely manner or a rapid progression of the anaphylactic event. Other studies have supported that older age and asthma may be associated with additional treatments, which may be a reflection of increased reaction severity. 4, 6 In the current study, all patients had reactions that met criteria for anaphylaxis and organ system involvement was similar among patients who received 1 versus 21 doses of epinephrine. following influenza vaccination (all were mild) 0 9 (5) 4 (9) 13 (6) 0 2 (3) 4 (9) 6 (6)
Significant differences with P values <.05 between severe and nonsevere egg-allergic patients are indicated in bold characters. *Measured with UniCAP for 2010-2011 and 2011-2012 and with Immulite for 2007-2010. There were 114 patients (including 36 severe cases) who had challenge with a baked good and tolerated it well. While the tolerance to baked goods in patients with severe allergy may suggest milder severity, this does not rule out the risk of severe reaction to uncooked egg proteins. àSome patients had more than 1 dose over several seasons. Percentage calculated on the total number of doses administered.
